Funding for this research was provided by:
Florida Department of Health (James Esther King (JEK) 8JK07, James Esther King (JEK) 9JK09, Bankhead Coley Grant 8BC07)
Sylvester Comprehensive Cancer Center, University of Miami Health Systems (Internal Funding, Internal Grant, Internal Funding)
University of Miami (Internal funding)
Received: 31 March 2022
Accepted: 23 June 2022
First Online: 24 August 2022
: The study was approved by the Ethics committees of the University of Miami, Miller School of Medicine. Animal experiments were approved by the IRB of the University of Miami. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Sylvester Comprehensive Cancer Center protocol code 20060858 approved on 6<sup>th</sup> June 2007.
: Not applicable.
: A.K.S. is one of the inventors of Minnelide, which has been licensed to Minneamrita Therapeutics by the University of Minnesota and is its cofounder and CSO. A.I. and W.A.T. are principals at Tymora Analytical Operations that developed and patented EVtrap. The rest of the authors declare no conflict of interest.